Similar to the way that HER2 is used to identify subtypes that are likely to respond to trastuzumab, RRM2 may be a predictive marker that can stratify the more fatal types of ER-negative breast cancers to identify breast cancer subtypes that will respond to RRM2 inhibitors. The gene discussed is ERBB2; the disease is breast carcinoma.